![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
News
Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals
Eiger BioPharmaceuticals Inc , announced an agreement to sell to Theragene Pharmaceuticals, Inc., a private biotechnology company, a non-strategic asset, Mydicar®. ...
Clinical Trials
Cannabics Pharmaceuticals Receives Positive Results In Drug Sensitivity Tests On CTCs
Cannabics Pharmaceuticals Inc announced it received positive results from screening necrosis (cell death) of circulating tumor cells, from cancer patients, treated with the cannabinoids...
Press Releases
Vitafoods Asia Elevates 2017 Learning Programme
Vitafoods Asia, the only event dedicated to the nutraceutical, functional food and beverages, and dietary supplement industries in Asia, announces the agenda for its...
Drug Research
eTheRNA advances in-vivo mRNA cancer immunotherapy into first oncology clinical studies
eTheRNA immunotherapies, a clinical-stage company developing mRNA based cancer immunotherapies from its unique TriMix platform, announces the start of the first Phase Ib oncology...
Industry Reports
Valeant Pharmaceuticals Completes Sale Of Dendreon To Sanpower Group
Valeant Pharmaceuticals International, Inc. announced that its affiliate has completed the sale of all of the outstanding equity interests in its former subsidiary Dendreon...
Packaging & Labelling
Pharmapack Europe 2018 to Spotlight New Innovations and the Young Innovators who are Shaping the Industry
Pharmapack Europe 2018 , Europe’s dedicated pharmaceutical packaging and drug delivery conference and exhibition, organised by UBM EMEA, is taking place on 7–8 February...
Drug Research
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China
Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read